Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers

Marjory Koller, Si-Qi Qiu, Matthijs D. Linssen, Liesbeth Jansen, Wendy Kelder, Jakob Vries, Inge Kruithof, Guo-Jun Zhang, Dominic J. Robinson, Wouter B. Nagengast, Annelies Jorritsma-Smit, Bert Vegt and Gooitzen M. Dam ()
Additional contact information
Marjory Koller: University of Groningen
Si-Qi Qiu: University of Groningen
Matthijs D. Linssen: University of Groningen
Liesbeth Jansen: University of Groningen
Wendy Kelder: Martini Hospital
Jakob Vries: University of Groningen
Inge Kruithof: Martini Hospital
Guo-Jun Zhang: Changjiang Scholar′s Laboratory of Shantou University Medical College
Dominic J. Robinson: Erasmus Medical Center Rotterdam
Wouter B. Nagengast: University of Groningen
Annelies Jorritsma-Smit: University of Groningen
Bert Vegt: University of Groningen
Gooitzen M. Dam: University of Groningen

Nature Communications, 2018, vol. 9, issue 1, 1-11

Abstract: Abstract During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-05727-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05727-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-05727-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().